Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Нервные болезни
2019 / N 2

Современные представления о лечении пациентов с транстиретиновой семейной амилоидной полиневропатией
Н.А. Супонева, А.С. Ризванова, Н.В. Белова

References

1. Freeman R, Barroso F. Recent advances in familial amyloid polyneuropathy. Current Opinion in Neurology 2015 Oct;28(5):494-9.
2. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle & Nerve 2007 Oct;36(4):411-23.
3. Sekijima Y. Recent progress in the understanding and treatment of transthyretin amyloidosis. Journal of Clinical Pharmacy and Therapeutics 2014 Jun;39(3):225-33.
4. Reilly MM, Adams D, Booth DR, Davis MB, Said G, Laubriat-Bianchin M, Pepys MB, Thomas PK, Harding AE. Transthyretin gene analysis in European patients with suspected familial amyloid polyneuropathy. Brain 1995 Aug;118(Pt 4):849-56.
5. Koike H, Misu K, Sugiura M, Iijima M, Mori K, Yamamoto M, Hattori N, Mukai E, Ando Y, Ikeda S, Sobue G. Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy. Neurology 2004 Jul;63(1):129-38.
6. Koike H, Tanaka F, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, Fujitake J, Kawanami T, Kato T, Yamamoto M, Sobue G. Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. Journal of Neurology, Neurosurgery, and Psychiatry 2012 Feb;83(2):152-8.
7. Koike H, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, Tanaka F, Sobue G. Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis. Amyloid 2011 Jun;18(2):53-62.
8. Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, Lewis WD, Obici L, Planté-Bordeneuve V, Rapezzi C, Said G, Salvi F. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet Journal of Rare Diseases 2013 Feb;8:31.
9. Maia LF, Magalhães R, Freitas J, Taipa R, Pires MM, Osório H, Dias D, Pessegueiro H, Correia M, Coelho T. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings. Journal of Neurology, Neurosurgery, and Psychiatry 2015 Feb;86(2):159-67.
10. Adams D, Suhr OB, Hund E, Obici L, Tournev I, Campistol JM, Slama MS, Hazenberg BP, Coelho T; European Network for TTR-FAP (ATTReuNET). First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Current Opinion in Neurology 2016 Feb;29(Suppl 1):S14-26.
11. Adams D, Cauquil C, Labeyrie C. Familial amyloid polyneuropathy. Current Opinion in Neurology 2017 Oct;30(5):481-9.
12. Conceição I, González-Duarte A, Obici L, Schmidt HH, Simoneau D, Ong ML, Amass L. “Red-flag” symptom clusters in transthyretin familial amyloid polyneuropathy. Journal of the Peripheral Nervous System 2016 Mar;21(1):5-9.
13. Adams D, Lozeron P, Lacroix C. Amyloid neuropathies. Current Opinion in Neurology 2012 Oct;25(5):564-72.
14. Ryzhkova DV, Makurova TV, Kozlenok AV, Mitrofanova LB. Scintigraphic diagnosis of transthyretin cardiac amyloidosis (demonstration of a clinical case). Russian Electronic Journal of Radiology 2017;7(1):117-22 (In Russian).
15. Naumova ES, Nikitin SS, Adyan TA, Druzhinin DS, Varshavskiy VA. Misdiagnosed case of transthyretin amyloidosis in a fully investigated patient. Neuromuscular Diseases 2018;8(1):46-52 (In Russian).
16. Wilczek HE, Larsson M, Ericzon BG; FAPWTR. Long-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR). Amyloid 2011 Jun;18(Suppl 1):193-5.
17. Adams D, Samuel D, Goulon-Goeau C, Nakazato M, Costa PM, Feray C, Planté V, Ducot B, Ichai P, Lacroix C, Metral S, Bismuth H, Said G. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain 2000 Jul;123(Pt 7):1495-504.
18. Holmgren G, Ericzon BG, Groth CG, Steen L, Suhr O, Andersen O, Wallin BG, Seymour A, Richardson S, Hawkins PN, Pepys MB. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. The Lancet 1993 May;341(8853):1113-6.
19. Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 2006 Dec;13(4):236-49.
20. Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, Heneghan MA, Gorevic PD, Litchy WJ, Wiesman JF, Nordh E, Corato M, Lozza A, Cortese A, Robinson-Papp J, Colton T, Rybin DV, Bisbee AB, Ando Y, Ikeda S, Seldin DC, Merlini G, Skinner M, Kelly JW, Dyck PJ; Diflunisal Trial Consortium. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013 Dec;310(24):2658-67.
21. Waddington Cruz M, Benson MD. A review of tafamidis for the treatment of transthyretin-related amyloidosis. Neurology and Therapy 2015 Dec;4(2):61-79.
22. Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Planté-Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Conceição IM, Schmidt HH, Trigo P, Kelly JW, Labaudinière R, Chan J, Packman J, Wilson A, Grogan DR. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012 Aug;79(8):785-92.
23. Coelho T, Maia LF, da Silva AM, Cruz MW, Planté-Bordeneuve V, Suhr OB, Conceiçao I, Schmidt HH, Trigo P, Kelly JW, Labaudinière R, Chan J, Packman J, Grogan DR. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. Journal of Neurology 2013 Nov;260(11):2802-14.
24. Merilini G, Planté-Bordeneuve V, Judge DP, Schmidt H, Obici L, Perlini S, Packman J, Tripp T, Grogan DR. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. Journal of Cardiovascular Translational Research 2013 Dec;6(6):1011-20.
25. Barroso FA, Judge DP, Ebede B, Li H, Stewart M, Amass L, Sultan MB. Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid 2017 Sep;24(3):194-204.
26. A database of clinical studies. Safety and efficacy evaluation of Fx-1006A in subjects with transthyretin amyloidosis. Available from: https://clinicaltrials.gov/ct2/show/NCT00925002 Accessed 2019 Jun 18.
27. Kapoor M, Rossor AM, Laura M, Reilly MM. Clinical presentation, diagnosis and treatment of TTR amyloidosis. Journal of Neuromuscular Diseases 2019;6(2):189-99.
28. Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Planté-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH 3rd, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB. Patisiran, an RNAi
therapeutic, for hereditary transthyretin amyloidosis. The New England Journal of Medicine 2018 Jul;379(1):11-21.
29. Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Planté-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceição I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T. Inotersen treatment
for patients with hereditary transthyretin amyloidosis. The New England Journal of Medicine 2018 Jul;379(1):22-31.
30. Maurer MS, Heitner S, Drachman B, Whelan C, Guthrie S, Tai L, Hughes SG, Monia BP, Ackermann EJ, Benson MD. Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO-TTR. Journal of the American College of Cardiology 2018 Mar;71(11 Suppl):A658.
31. Gertz M, Wang AK, Coelho T, Waddington-Cruz M, Polydefkis MJ, Dyck PJ, Scheinberg M, Planté-Bordeneuve V, Berk J, Barroso F, Adams D, Brannagan T, Whelan C, Merlini G, Drachman BM, Heitner SB, Conceição I, Schmidt H, Vita G, Campistol JM, Gamez J, Gane E, Gorevic P, Souza Bulle Oliveira A, Monia BP, Hughes SG, Kwoh J, McEvoy BW, Baker BF, Ackermann EJ, Benson MD. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO-TTR). Neurology 2018
Apr;90(15 Suppl):N2.001.
32. Brannagan T, Wang AK, Coelho T, Waddington-Cruz M, Polydefkis MJ, Dyck PJ, Scheinberg M, Planté-Bordeneuve V, Berk J, Barroso F, Adams D, Whelan C, Merlini G, Drachman BM, Heitner SB, Conceição I, Schmidt H, Vita G, Campistol JM, Gamez J, Gore vic P, Monia BP, Hughes SG, Kwoh J, McEvoy BW, Baker BF, Ackermann EJ, Benson MD, Gertz M. Open label extension of the phase 3 study NEURO-TTR to assess the long-term efficacy and
safety of inotersen in patients with hereditary transthyretin amyloidosis. Neurology 2018 Apr;90(15 Suppl):P1.324.
33. De Genst E, Messer A, Dobson CM. Antibodies and protein misfolding: from structural research tools to therapeutic strategies. Biochimica et Biophysica Acta 2014 Nov;1844(11):1907-19.
34. Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ, Minogue S, Dhillon AP, Taylor GW, Bradwell AR, Petrie A, Gillmore JD, Bellotti V, Botto M, Hawkins PN, Pepys MB. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010 Nov;468(7320):93-7.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]